



## About HRA Pharma

HRA Pharma is a privately-held emerging pharma company that engineers drugs, devices and services in reproductive health and endocrinology and makes them available worldwide.

By targeting niche market segments and designing custom-made solutions, our objective is to fill therapeutic gaps. A young and growing company headquartered in Paris, we consider Europe as our home market and our mindset is international.

HRA Pharma makes the difference by combining its health mission with a socially conscious approach to ensuring that its products are accessible everywhere.

### Specialty products

The company's products in the reproductive health include hormonal contraceptives, intrauterine devices (IUD) and other products for gynecological use. Norlevo<sup>®</sup>, HRA Pharma's first product was launched in France in 1999. It was the first progestin-only emergency contraceptive pill to be approved in the Western world and to be granted a non-prescription status, making it broadly accessible. It is now available in over 60 countries. The company's other products in this field include ellaOne<sup>®</sup>, a new generation emergency contraceptive, Gymiso<sup>®</sup>, a prostaglandin for use in obstetrics and gynecology, Cicatridine<sup>®</sup> which promotes vaginal healing and Mona-Lisa<sup>®</sup>, a copper contraceptive IUD.

In the field of endocrine diseases, HRA Pharma commercializes Lysodren<sup>®</sup> that contains the active substance mitotane. This product has been granted an "orphan drug" status in 2002 and obtained a European Market Authorization in 2004. It is now commercialized in all the European Union member states. Moreover, in order to assist healthcare professionals in the treatment of patients with this disease, HRA Pharma has developed a European mitotane plasma level testing network called Lysosafe Service. It is a free of charge service permitting to optimize the efficacy of the treatment by adapting its daily dose and controlling patients' tolerance.

### HRA PHARMA QUICK FACTS

#### LOCATIONS

Headquarters Paris, France  
Local offices Bochum, Germany  
London, UK  
New York City, US

#### STAFF

70-member multinational team

#### CHAIRMAN

André Ulmann

#### CHIEF EXECUTIVE OFFICER

Erin Gainer

#### 2008 FINANCIAL HIGHLIGHTS

Total Revenue >33,8 M€  
R&D investment ~ 20%

#### MAIN PRODUCTS

ellaOne<sup>®</sup> (ulipristal acetate)  
NorLevo<sup>®</sup> (levonorgestrel)  
Lysodren<sup>®</sup> (mitotane)  
Mona-Lisa<sup>®</sup> (copper-IUD)

#### CONTACT

HRA Pharma  
15 rue Béranger  
75003 Paris, France  
T : +33 1 40 33 11 30  
F : +33 1 40 33 12 31  
E : [info@hra-pharma.com](mailto:info@hra-pharma.com)

## Innovative projects

HRA Pharma is currently developing a number of products for reproductive health and endocrine diseases. In addition the company takes active part in the emergence of regenerative medicine by supporting enhancement of cell-based technologies via its subsidiary Celogos. Details of these product candidates' status are shown below:

	Pre clinical	Phase I	Phase II	Phase III
<b>REPRODUCTIVE HEALTH</b>				
ella/ ellaOne <sup>(1)</sup> Emergency contraception				
HRA 081025 Contraception				
HRA 081035 Contraception				
UPA-UF <sup>(1)</sup> Uterine fibroids				
UPA-VR <sup>(1)</sup> Vaginal ring contraception				
UPA-IUS <sup>(1)</sup> Intra uterine system contraception				
<b>ENDOCRINE DISEASES</b>				
Mifedren <sup>®</sup> Ectopic Cushing's syndrome				
HRA 072033 Orphan drug				
<b>CELL THERAPY (via our subsidiary CELOGOS)</b>				
RCD1 Urinary incontinence				
RCD2 Anal incontinence				

(1) New chemical entity under development

## Strong corporate commitment

HRA Pharma was founded by a team of medical specialists who genuinely care about global healthcare. Making its products available for the poorest has been a corporate commitment of the company's shareholders and management since onset. HRA has invested significant effort in establishing strong links with international NGOs and local authorities. The company has thereby participated in a range of actions aimed to promote education on contraception and facilitate access to products in the most remote and poorest parts of the world.

To know more about our access projects in this area, please visit [www.actionshrapharma.com](http://www.actionshrapharma.com)



Actions HRA Pharma

## HISTORY

1996	Foundation of the company
1998	NorLevo <sup>®</sup> launched in France
1999	HRA Pharma becomes profitable NorLevo <sup>®</sup> approved for sale throughout Europe
2002	Lysodren <sup>®</sup> granted orphan drug status in Europe.
2004	Lysodren <sup>®</sup> launched in 27 countries throughout Europe Launch of Lysosafe
2005	Acquisition of Celogos
2006	Launch of Mona Lisa <sup>®</sup> IUD in France Launch of "Mona Lisa Afrique" program
2008	Establishment of a German subsidiary
2009	HRA Pharma granted European marketing authorization for ellaOne <sup>®</sup>  Establishment of a British subsidiary

## PARTNERING

Building effective partnerships and collaborative relationships is a priority for HRA Pharma. We currently have a strong network of over 50 partners worldwide.

We are always interested to hear from partners who wish to manufacture, distribute our products in defined territories, or to help us further develop our product candidates. If you are interested in partnering with HRA Pharma, contact [busdev@hra-pharma.com](mailto:busdev@hra-pharma.com).